ライフサイエンスコーパス: hyperinsulinemic

1 wing treatment protocols, all rats underwent hyperinsulinemic (0.2 units kg(-1) min(-1)), severe hypo

2 On the fourth day, rats were subjected to a hyperinsulinemic (0.2 units x kg(-1) x min(-1)) severe h

3 In protocols 1-4, 3-h hyperinsulinemic (0.2 units/kg/min) and hypoglycemic (10

4 pups were glucose intolerant (P = 0.04) and hyperinsulinemic (1.3-fold increase, P = 0.02) by 1 mont

5 360-600 min, the remaining dogs underwent a hyperinsulinemic (4x basal) hyperglycemic clamp (arteria

6 Day 1 consisted of either two 2-h hyperinsulinemic (812 +/- 50 pmol/L)-euglycemic (5 +/- 0

7 50 pmol/L)-euglycemic (5 +/- 0.1 mmol/L) or hyperinsulinemic (812 +/- 50 pmol/L)-hypoglycemic (2.9 +

8 al diet had reduced perigonadal fat but were hyperinsulinemic and by age 12 months, were insulin defi

9 insulin receptor substrate-1 (IRS1-het) are hyperinsulinemic and insulin resistant during pregnancy,

10 ably, obese patients with MC4R mutations are hyperinsulinemic and resistant to obesity-induced hypert

11 sed CB(1) specifically in hepatocytes became hyperinsulinemic as a result of reduced insulin clearanc

12 ctose but in the presence of a hyperglycemic-hyperinsulinemic challenge including portal vein glucose

13 SI was measured using euglycemic-hyperinsulinemic clamp (EGC), before (week 0 [w0]) and a

14 In this prospective study, euglycemic hyperinsulinemic clamp (EHC) was performed at second (D2

15 Euglycemic-hyperinsulinemic clamp (EHC) was preformed to assess the

16 before and 1 month after RYGB by euglycemic hyperinsulinemic clamp (EHC), by intravenous glucose tol

17 nfirmed by [6-6-2H2]-glucose-labeled, 2-step hyperinsulinemic clamp (n = 20).

18 dilution, insulin sensitivity by euglycemic-hyperinsulinemic clamp (steady-state glucose utilization

19 Here we show that initiation of a euglycemic-hyperinsulinemic clamp 4 h after single-legged exercise

20 During a postprandial hyperglycemic-hyperinsulinemic clamp after SGLT2-I treatment, E-Rd inc

21 Insulin sensitivity (S(I)) was assessed by hyperinsulinemic clamp and lean body mass (LBM) and tota

22 A euglycemic-hyperinsulinemic clamp and skeletal muscle biopsies were

23 nge in IR assessed using a 2-step euglycemic-hyperinsulinemic clamp combined with infusion of tritiat

24 , or glucose disposal rates under euglycemic hyperinsulinemic clamp conditions (SMD: 0.00; 95% CI: 20

25 sue in overweight subjects who had undergone hyperinsulinemic clamp experiments.

26 However, the hyperinsulinemic clamp increased brain glucose metabolis

27 is, eight healthy men underwent a euglycemic-hyperinsulinemic clamp on 2 separate days: one day with

28 ds to assess resistance are available (e.g., hyperinsulinemic clamp or minimal model), but surrogate

29 od before the initiation of the hypoglycemic-hyperinsulinemic clamp protocol and during the last 30 m

30 Euglycemic-hyperinsulinemic clamp studies confirmed the marked impr

31 Euglycemic-hyperinsulinemic clamp studies demonstrate that deletion

32 n synthesis compared with WT controls during hyperinsulinemic clamp studies.

33 as similar to that in control muscles during hyperinsulinemic clamp studies.

34 was increased during fasting but not during hyperinsulinemic clamp studies.

35 before (basal period) and during euglycemic-hyperinsulinemic clamp studies.

36 2 weeks after treatment using the euglycemic hyperinsulinemic clamp technique.

37 conducted a meal challenge and a euglycemic-hyperinsulinemic clamp to evaluate insulin sensitivity a

38 her saline infusion (sham) or an isoglycemic-hyperinsulinemic clamp using B28-Asp-insulin (which can

39 A hyperglycemic-hyperinsulinemic clamp was established in the presence o

40 igitorum longus muscle during the euglycemic-hyperinsulinemic clamp was increased in lean gamma3(R225

41 y and muscle insulin sensitivity (euglycemic-hyperinsulinemic clamp with 2-deoxyglucose) and fat util

42 , muscle, and adipose tissue by a euglycemic hyperinsulinemic clamp with 3-(3)H-glucose.

43 sulin sensitivity was analyzed by euglycemic-hyperinsulinemic clamp, and molecular tools were used to

44 atients at risk for CIM underwent euglycemic-hyperinsulinemic clamp, muscle microdialysis studies, an

45 During the hyperinsulinemic clamp, the glucose infusion rate (GIR)

46 During euglycemic-hyperinsulinemic clamp, there is no suppression of hepat

47 ssociation of genetic scores with euglycemic-hyperinsulinemic clamp- and oral glucose tolerance test-

48 n resistance, as verified using a euglycemic/hyperinsulinemic clamp.

49 sitivity was quantitated with the euglycemic-hyperinsulinemic clamp.

50 glucose production as assessed by euglycemic hyperinsulinemic clamp.

51 e conditions and during a hyperaminoacidemic-hyperinsulinemic clamp.

52 obtained before and after 8-h hyperglycemic-hyperinsulinemic clamping in 13 normal subjects and in 6

53 Subjects were also studied by euglycemic-hyperinsulinemic clamps performed at rest and 3 h after

54 rticipants without diabetes underwent paired hyperinsulinemic clamps separated by 4 weeks.

55 mmol/L (50 mg/dl) for 1 hour by incremental hyperinsulinemic clamps using baseline and 24 hour sampl

56 pre- and 3 months post-RYGB, and euglycemic-hyperinsulinemic clamps were used to assess insulin sens

57 ree different occasions during hyperglycemic-hyperinsulinemic clamps with concomitant infusions of GI

58 sensitivity, as measured by using euglycemic-hyperinsulinemic clamps with infusion of [6,6-(2)H(2)]gl

59 rs with DM and 19 control subjects underwent hyperinsulinemic clamps with maintained sequential hyper

60 nsulin in vivo in mice undergoing euglycemic-hyperinsulinemic clamps, being highly up-regulated in li

61 ed glucose uptake measured during euglycemic-hyperinsulinemic clamps, suggesting a role of beige cell

62 c (5.0 mmol/L) and hypoglycemic (2.8 mmol/L) hyperinsulinemic clamps, we compared brain activation re

63 oral glucose tolerance tests and euglycemic-hyperinsulinemic clamps.

64 eripheral insulin resistance, they were less hyperinsulinemic during a glucose tolerance test because

65 0 each, with and without diabetes) underwent hyperinsulinemic euglycaemic clamp and mixed meal test,

66 insulinemic hypoglycemia (bolus insulin), 2) hyperinsulinemic euglycemia (bolus insulin and glucose i

67 nsulinemic clamps with maintained sequential hyperinsulinemic euglycemia (plasma glucose, 90 mg/dL [5

68 eline, the subsequent changes in MBFR during hyperinsulinemic euglycemia and hyperinsulinemic hypogly

69 e dipyridamole stress at baseline and during hyperinsulinemic euglycemia and hyperinsulinemic hypogly

70 In control subjects, MBFR increased during hyperinsulinemic euglycemia by 0.57 U (22%) above baseli

71 espectively, (all P < 0.01) during zinc-free hyperinsulinemic euglycemia over the first 60 min.

72 Hyperinsulinemic euglycemic (5 mmol/L) and hypoglycemic

73 ight fast, all subjects underwent a two-step hyperinsulinemic euglycemic (5.0 mmol/L)-hypoglycemic (2

74 Day 1 involved hyperinsulinemic euglycemic (90 mg/dL x 1 h), then hypog

75 ealthy non-diabetic participants underwent a hyperinsulinemic euglycemic (92+/-3 mg/dL) - hypoglycemi

76 For this purpose, hyperinsulinemic euglycemic and hypoglycemic glucose cla

77 resonance (MR) imaging system combined with hyperinsulinemic euglycemic clamp (HEC) was used.

78 ,3,3-(2)H(5)]glycerol, in combination with a hyperinsulinemic euglycemic clamp during the last 3 hrs.

79 taken from both legs before and after a 3-h hyperinsulinemic euglycemic clamp performed 3 h after a

80 ulin sensitivity was determined by using the hyperinsulinemic euglycemic clamp procedure.

81 The hyperinsulinemic euglycemic clamp revealed that VDR acti

82 ion and glucose clearance were quantified by hyperinsulinemic euglycemic clamp studies and pyruvate t

83 However, hyperinsulinemic euglycemic clamp studies revealed impro

84 Furthermore, hyperinsulinemic euglycemic clamp studies showed no diff

85 Hyperinsulinemic euglycemic clamp studies showed that th

86 enhanced systemic insulin sensitivity during hyperinsulinemic euglycemic clamp studies.

87 A hyperinsulinemic euglycemic clamp was used to compare ti

88 raphy), insulin sensitivity (measured with a hyperinsulinemic euglycemic clamp with [6,6-(2)H(2)]-glu

89 aging (MRI), and insulin sensitivity using a hyperinsulinemic euglycemic clamp with a glucose isotope

90 o metabolic (oral glucose tolerance test and hyperinsulinemic euglycemic clamp) and imaging studies (

91 of glucose turnover and insulin sensitivity (hyperinsulinemic euglycemic clamp) were performed before

92 R or RES training on insulin sensitivity (by hyperinsulinemic euglycemic clamp), body composition (by

93 Insulin sensitivity was analyzed by a 2-step hyperinsulinemic euglycemic clamp, and postprandial inte

94 sessed during steady-state conditions with a hyperinsulinemic euglycemic clamp.

95 etion pattern between a baseline study and a hyperinsulinemic euglycemic clamp.

96 This finding was confirmed with the use of hyperinsulinemic euglycemic clamping, showing a glucose

97 Hyperinsulinemic euglycemic clamps were performed to det

98 itivity between 0 and 6 weeks as measured by hyperinsulinemic euglycemic clamps.

99 in at low rates (stages 1 and 2 of a 3-stage hyperinsulinemic euglycemic pancreatic clamp).

100 unctional MRI (fMRI) combined with a stepped hyperinsulinemic euglycemic-hypoglycemic clamp and behav

101 rculating insulin and glucose levels through hyperinsulinemic, euglycemic clamp studies.

102 insulin sensitivity were assessed using the hyperinsulinemic- euglycemic clamp combined with the glu

103 cells (PBMCs) and monocytes obtained during hyperinsulinemic-euglycemic (5.0 mmol/L)-hypoglycemic (2

104 inine (GPA) test, insulin sensitivity from a hyperinsulinemic-euglycemic (EU) clamp, and glucose coun

105 Hyperglycemic (HG) and hyperinsulinemic-euglycemic (HI) clamps were performed t

106 A hyperinsulinemic-euglycemic and a hyperglycemic clamp we

107 We assessed glucose homeostasis by hyperinsulinemic-euglycemic and hyperglycemic clamp stud

108 Insulin action was measured by a three-stage hyperinsulinemic-euglycemic clamp (4, 8, and 40 mU/m(2)/

109 Twenty-three patients underwent a two-step hyperinsulinemic-euglycemic clamp (HEC) with glucose tra

110 e insulin sensitivity was determined using a hyperinsulinemic-euglycemic clamp (SIClamp, insulin rate

111 Hyperinsulinemic-euglycemic clamp analysis 8 weeks after

112 Female mice were assessed by hyperinsulinemic-euglycemic clamp analysis and indirect

113 Hyperinsulinemic-euglycemic clamp analysis was used to a

114 ndrial function in type 1 diabetes using the hyperinsulinemic-euglycemic clamp and (31)P-MRS before,

115 tivity and secretion were evaluated by a 3-h hyperinsulinemic-euglycemic clamp and a 2-h hyperglycemi

116 tic tissue extraction are not clear.METHODSA hyperinsulinemic-euglycemic clamp and a 3-hour oral gluc

117 Assessments by hyperinsulinemic-euglycemic clamp and a glucose toleranc

118 beginning and end of each dietary period, a hyperinsulinemic-euglycemic clamp and an intravenous glu

119 Insulin sensitivity was measured by hyperinsulinemic-euglycemic clamp and insulin secretion

120 e, and secretion and glucose tolerance using hyperinsulinemic-euglycemic clamp and intravenous and or

121 cose tolerance and insulin sensitivity using hyperinsulinemic-euglycemic clamp and muscle insulin rec

122 in sensitivity (SI(clamp)) was studied using hyperinsulinemic-euglycemic clamp at baseline and at 4 m

123 cTg mice were highly insulin sensitive under hyperinsulinemic-euglycemic clamp conditions, eliminatin

124 The hyperinsulinemic-euglycemic clamp experiment showed that

125 Hyperinsulinemic-euglycemic clamp experiments show, for

126 olerance tests, insulin tolerance tests, and hyperinsulinemic-euglycemic clamp experiments.

127 ion (r = 0.31, P < 0.05) and negatively with hyperinsulinemic-euglycemic clamp glucose infusion rate

128 body glucose metabolism, as assessed during hyperinsulinemic-euglycemic clamp in awake mice.

129 In addition, infusion of insulin during a hyperinsulinemic-euglycemic clamp induced conspicuous ER

130 ipheral insulin sensitivity, measured by the hyperinsulinemic-euglycemic clamp method.

131 During hyperinsulinemic-euglycemic clamp of diabetic KKA(Y) mic

132 rations, under basal conditions and during a hyperinsulinemic-euglycemic clamp procedure (HECP), with

133 y insulin sensitivity was assessed using the hyperinsulinemic-euglycemic clamp procedure in conjuncti

134 d after treatment was evaluated by using the hyperinsulinemic-euglycemic clamp procedure in conjuncti

135 A two-stage hyperinsulinemic-euglycemic clamp procedure in conjuncti

136 473), and p-AKT(Thr308) in 22 women during a hyperinsulinemic-euglycemic clamp procedure with and wit

137 rcentage increase in glucose uptake during a hyperinsulinemic-euglycemic clamp procedure).

138 A hyperinsulinemic-euglycemic clamp procedure, in conjunct

139 Hyperinsulinemic-euglycemic clamp reveals an increased g

140 Hyperinsulinemic-euglycemic clamp studies demonstrated t

141 Hyperinsulinemic-euglycemic clamp studies indicate that

142 Hyperinsulinemic-euglycemic clamp studies reveal that th

143 Hyperinsulinemic-euglycemic clamp studies revealed signi

144 Hyperinsulinemic-euglycemic clamp studies show that BAM1

145 Hyperinsulinemic-euglycemic clamp studies showed that ad

146 Hyperinsulinemic-euglycemic clamp studies suggest that D

147 increased hepatic insulin sensitivity during hyperinsulinemic-euglycemic clamp studies, which was ass

148 vity in 26 diabetic subjects was assessed by hyperinsulinemic-euglycemic clamp studies.

149 cific insulin sensitivity were determined by hyperinsulinemic-euglycemic clamp studies.

150 Glucose metabolism was investigated by hyperinsulinemic-euglycemic clamp studies.

151 In addition, a hyperinsulinemic-euglycemic clamp suggests that intracer

152 Improvement was assessed by using the hyperinsulinemic-euglycemic clamp technique.

153 VN, in combination with isotope dilution and hyperinsulinemic-euglycemic clamp techniques.

154 us of amino acids was administered and a 3-h hyperinsulinemic-euglycemic clamp was commenced ("fed" p

155 The glucose infusion rate during a hyperinsulinemic-euglycemic clamp was increased by 50% i

156 n sensitivity in Wistar rats assessed by the hyperinsulinemic-euglycemic clamp was minimally affected

157 During the last 2 h, a hyperinsulinemic-euglycemic clamp was performed.

158 ecific insulin sensitivity was assessed by a hyperinsulinemic-euglycemic clamp with [6,6-(2)H2]-gluco

159 A hyperinsulinemic-euglycemic clamp with femoral arteriove

160 e SAs and 12 matched Cs underwent a two-step hyperinsulinemic-euglycemic clamp with skeletal muscle b

161 epatic insulin sensitivity (assessed using a hyperinsulinemic-euglycemic clamp with stable isotope tr

162 nd during a two-step (10 and 20 mU/m(2)/min) hyperinsulinemic-euglycemic clamp with stable isotopes,

163 ssion: with and without insulin stimulation (hyperinsulinemic-euglycemic clamp) using [18F]fluorodeox

164 a], [(2)H5]glycerol at baseline and during a hyperinsulinemic-euglycemic clamp), lipid oxidation (ind

165 ences in insulin sensitivity, as measured by hyperinsulinemic-euglycemic clamp, and skeletal muscle m

166 During the hyperinsulinemic-euglycemic clamp, retrodialysis of dexa

167 -fold more insulin sensitive, as measured by hyperinsulinemic-euglycemic clamp, than C57BL/6 wild-typ

168 and BMI-matched controls (n = 6) underwent a hyperinsulinemic-euglycemic clamp, VO2max test, dual-ene

169 ere hepatic insulin resistance assessed by a hyperinsulinemic-euglycemic clamp, which could mostly be

170 whole-body and leg glucose disposal during a hyperinsulinemic-euglycemic clamp, while decreasing hepa

171 ody insulin sensitivity was measured using a hyperinsulinemic-euglycemic clamp.

172 and augments muscle glucose uptake during a hyperinsulinemic-euglycemic clamp.

173 of endogenous glucose production during the hyperinsulinemic-euglycemic clamp.

174 ted with insulin sensitivity measured by the hyperinsulinemic-euglycemic clamp.

175 derwent whole-body [(18)F]FDG-PET/MRI during hyperinsulinemic-euglycemic clamp.

176 study comprised a 5-h basal period and a 3-h hyperinsulinemic-euglycemic clamp.

177 atheters during a 3-h basal period and a 3-h hyperinsulinemic-euglycemic clamp.

178 opsied skeletal muscles at the baseline of a hyperinsulinemic-euglycemic clamp.

179 Metabolic parameters were determined by hyperinsulinemic-euglycemic clamp.

180 Insulin resistance was assessed by a hyperinsulinemic-euglycemic clamp.

181 In vivo glucose metabolism was evaluated by hyperinsulinemic-euglycemic clamp.

182 ted glucose disposal (M) measured during the hyperinsulinemic-euglycemic clamp.

183 small animal PET system was performed under hyperinsulinemic-euglycemic clamp.

184 s artery diameter at baseline and during the hyperinsulinemic-euglycemic clamp.

185 sensitivity (M-value) was determined using a hyperinsulinemic-euglycemic clamp.

186 letal muscle glucose uptake as measured by a hyperinsulinemic-euglycemic clamp.

187 pearance, and muscle glucose uptake during a hyperinsulinemic-euglycemic clamp.

188 r intralipid/heparin-infusion (high FFA) and hyperinsulinemic-euglycemic clamping (low FFA) in a rand

189 Hyperinsulinemic-euglycemic clamping studies revealed th

190 ith monogenic or polygenic obesity underwent hyperinsulinemic-euglycemic clamping with concomitant ad

191 ects underwent studies comparing fasting and hyperinsulinemic-euglycemic clamping with tracer infusio

192 nt-infusion administration of tracers during hyperinsulinemic-euglycemic clamping.

193 IL-10 (M(IL10)) and in wild-type mice during hyperinsulinemic-euglycemic clamping.

194 derwent the mixed meal tolerance test (MMT), hyperinsulinemic-euglycemic clamps (HECs), and skeletal

195 Hyperinsulinemic-euglycemic clamps and signaling studies

196 nd women underwent research tests, including hyperinsulinemic-euglycemic clamps and vastus lateralis

197 er day) or vehicle treatment, mice underwent hyperinsulinemic-euglycemic clamps combined with radiola

198 Hyperinsulinemic-euglycemic clamps confirmed enhanced in

199 Hyperinsulinemic-euglycemic clamps in DIO mice revealed

200 ity using glucose tolerance tests (GTTs) and hyperinsulinemic-euglycemic clamps in mouse models of ty

201 hyperinsulinemia to insulin resistance using hyperinsulinemic-euglycemic clamps in three participant

202 integrin interaction in IR was studied using hyperinsulinemic-euglycemic clamps on integrin alpha(2)b

203 involved one of the following: 1) two 90-min hyperinsulinemic-euglycemic clamps plus naloxone infusio

204 Hyperinsulinemic-euglycemic clamps revealed no differenc

205 a, investigation of insulin resistance using hyperinsulinemic-euglycemic clamps revealed no significa

206 We used hyperinsulinemic-euglycemic clamps to show a bona fide c

207 ance spectroscopy to assess IMCL content and hyperinsulinemic-euglycemic clamps using [6,6-(2)H(2)] g

208 etabolic profile, and insulin sensitivity by hyperinsulinemic-euglycemic clamps were examined.

209 s and oral-glucose-tolerance test (OGTT) and hyperinsulinemic-euglycemic clamps were performed to ass

210 Hyperinsulinemic-euglycemic clamps were used to assess i

211 uced by dietary methionine restriction (MR), hyperinsulinemic-euglycemic clamps were used to examine

212 ivity using acute insulin administration and hyperinsulinemic-euglycemic clamps with [(3)H]glucose in

213 First, we performed hyperinsulinemic-euglycemic clamps with concurrent hippo

214 Twenty-one men underwent two hyperinsulinemic-euglycemic clamps with d-[6,6-(2)H2]glu

215 s naloxone infusion (control); 2) two 90-min hyperinsulinemic-euglycemic clamps with exercise at 60%

216 ped hyperinsulinemic-hypoglycemic and paired hyperinsulinemic-euglycemic clamps with infusion of 6,6-

217 tic resonance spectroscopy before and during hyperinsulinemic-euglycemic clamps with isotope dilution

218 ay absorptiometry), insulin sensitivity (via hyperinsulinemic-euglycemic clamps), and insulin secreti

219 Using direct measures (i.e., hyperinsulinemic-euglycemic clamps), we examined the rel

220 increased glucose disposal rate (measured by hyperinsulinemic-euglycemic clamps).

221 ased on glucose and insulin tolerance tests, hyperinsulinemic-euglycemic clamps, and insulin signalin

222 glucose production in isolated hepatocytes, hyperinsulinemic-euglycemic clamps, liver triglyceride c

223 ed by broad metabolic phenotyping, including hyperinsulinemic-euglycemic clamps, magnetic resonance s

224 Using hyperinsulinemic-euglycemic clamps, we studied insulin a

225 ivity (M value) was assessed with the use of hyperinsulinemic-euglycemic clamps.

226 sing glucose and insulin tolerance tests and hyperinsulinemic-euglycemic clamps.

227 Under hyperinsulinemic-euglycemic conditions, hepatic insulin

228 Insulin sensitivity was assessed by hyperinsulinemic-euglycemic glucose clamp before and aft

229 A 2-stage hyperinsulinemic-euglycemic insulin clamp was used to me

230 Day 1 consisted of morning and afternoon 2-h hyperinsulinemic-euglycemic or hypoglycemic clamps with

231 ose uptake) as assessed by using a two-stage hyperinsulinemic-euglycemic pancreatic clamp procedure i

232 In hyperinsulinemic-euglycemic wild type mice, renal Bmf ex

233 In obese, hyperglycemic, hyperinsulinemic female Lepr(db/db) mice, GE was acceler

234 rmined systemic glucose uptake by euglycemic-hyperinsulinemic glucose clamp in 15 normal-weight and 1

235 mmol/L), and during recovery (5-6 mmol/L) by hyperinsulinemic glucose clamp.

236 -glucose positron emission tomography during hyperinsulinemic glucose clamps at nominal plasma glucos

237 asting plasma insulin <11.2 mU/L, n = 18) or hyperinsulinemic (HI) (fasting plasma insulin >11.2 mU/L

238 ulinemic-euglycemic clamp) and postprandial (hyperinsulinemic hyperaminoacidemic-euglycemic clamp) co

239 uscle protein synthesis rates in response to hyperinsulinemic-hyperaminoacidemic clamps.

240 ct and store more glucose in the presence of hyperinsulinemic hyperglycemia later in the same day, in

241 e, we describe a novel method for therapy of hyperinsulinemic hyperglycemia, highly selectively killi

242 To understand the fate of ICCs in hyperinsulinemic, hyperglycemic states characterized by

243 ubset of dogs (SHAM, n = 5; CHADN, n = 6), a hyperinsulinemic-hyperglycemic clamp was used to assess

244 -fat and -fructose diet [P-HFF]) underwent a hyperinsulinemic-hyperglycemic clamp with intraportal gl

245 examined on three randomized study days: 1) hyperinsulinemic hypoglycemia (bolus insulin), 2) hyperi

246 Hyperinsulinemic hypoglycemia (HI) and congenital polycy

247 Postprandial hyperinsulinemic hypoglycemia (PHH) is often reported af

248 glucose, 90 mg/dL [5.0 mmol/L]) followed by hyperinsulinemic hypoglycemia (plasma glucose, 50 mg/dL

249 0.38 to 0.75; P<0.0001) and decreased during hyperinsulinemic hypoglycemia by 0.36 U (14%) below base

250 -controlled cross-over trial using a stepped hyperinsulinemic hypoglycemia clamp was performed in 12

251 MBFR during hyperinsulinemic euglycemia and hyperinsulinemic hypoglycemia in DM patients were simila

252 Congenital hyperinsulinemic hypoglycemia is a group of genetic diso

253 Treatment of hyperinsulinemic hypoglycemia is challenging.

254 Hyperinsulinemic hypoglycemia is the most common cause o

255 d in type 2 diabetes, neonatal diabetes, and hyperinsulinemic hypoglycemia of infancy (HHI).

256 oop variant and GCK variants associated with hyperinsulinemic hypoglycemia reveal two distinct mechan

257 -1 in postprandial glycemia in patients with hyperinsulinemic hypoglycemia syndrome after gastric byp

258 ibitor sirolimus in four infants with severe hyperinsulinemic hypoglycemia that had been unresponsive

259 The treatment of hyperinsulinemic hypoglycemia that is unresponsive to di

260 Methods: Six patients with hyperinsulinemic hypoglycemia were included.

261 thase activity was completely ablated during hyperinsulinemic hypoglycemia, and catecholamine signali

262 oss-over order on 5 patients with endogenous hyperinsulinemic hypoglycemia.

263 vasive, highly specific treatment method for hyperinsulinemic hypoglycemia.

264 ns causing monogenic diabetes and congenital hyperinsulinemic hypoglycemia.

265 roven in critically ill children at risk for hyperinsulinemic hypoglycemia.

266 receptor 1 (SUR1)/ABCC8 from a patient with hyperinsulinemic hypoglycemia.

267 e and during hyperinsulinemic euglycemia and hyperinsulinemic hypoglycemia.

268 earched for relevant literature on exogenous hyperinsulinemic hypoglycemia.

269 can help guide the management of iatrogenic hyperinsulinemic hypoglycemia.

270 geted microinjection of ephrinA5-Fc before a hyperinsulinemic hypoglycemic clamp study caused a reduc

271 participants (n = 10 per group) underwent a hyperinsulinemic-hypoglycemic (2.6 mmol/L) clamp, either

272 ahepatic islet transplantation using stepped hyperinsulinemic-hypoglycemic and paired hyperinsulinemi

273 3 weeks (range 19-25) after GBP surgery with hyperinsulinemic-hypoglycemic clamp (stepwise to plasma

274 lus-induced hypoglycemia test and a low-dose hyperinsulinemic-hypoglycemic clamp procedure.

275 Subsequently, a hyperinsulinemic-hypoglycemic clamp study was performed.

276 Day 2 consisted of a single 2-h hyperinsulinemic-hypoglycemic clamp.

277 diaphragmatic vagotomy (TSV) were exposed to hyperinsulinemic-hypoglycemic clamps where glycemia was

278 Furthermore, during hyperinsulinemic-hypoglycemic clamps, ghrelin-KO mice re

279 On day 2, all were studied with stepped hyperinsulinemic-hypoglycemic clamps, using hormone conc

280 sing a catecholamine-specific neurotoxin and hyperinsulinemic-hypoglycemic clamps, we found that symp

281 entrations in the VMH were assessed during a hyperinsulinemic-hypoglycemic glucose clamp study in chr

282 th no fructose infusion followed by a 2-hour hyperinsulinemic/hypoglycemic clamp.

283 imental approaches: 1) glucose gavage and 2) hyperinsulinemic intravenous infusion, for studies in ei

284 the beta-cell-deficient obese hyperglycemic/hyperinsulinemic KS db/db mouse model was used to assess

285 his DNA region was confirmed in the heart of hyperinsulinemic mice.

286 thotopic mammary tumors in control FVB/n and hyperinsulinemic MKR mice, and treated them with the ins

287 BEZ235 decreased mammary tumor growth in the hyperinsulinemic MKR mouse.

288 ty both in in vitro and in vivo diet-induced hyperinsulinemic mouse model.

289 They underwent hyperinsulinemic-normoglycemic clamps with [6,6-(2)H2]gl

290 y, Tregs from the visceral adipose tissue of hyperinsulinemic, obese mice showed a similar specific d

291 f weight reduction on vascular function with hyperinsulinemic patients deriving the greatest benefit.

292 During the hyperinsulinemic period, OLZ-ICV caused a decreased GIR,

293 tigate how severe hypoglycemia can be fatal, hyperinsulinemic, severe hypoglycemic (10-15 mg/dL) clam

294 l tangles, presently observed aberrations in hyperinsulinemic states may participate in linking insul

295 Conserved activation of hepatic aPKC in hyperinsulinemic states of T2DM, obesity and MetSyn is p

296 In hyperinsulinemic states, myocardin may act as a nuclear

297 or underlying this is dyslipidemia, which in hyperinsulinemic subjects with early type 2 diabetes is

298 yperglycemia or albuminuria, fa/fa rats were hyperinsulinemic with high urinary IGF1/2 excretion, gai

299 se mice: mice with normal glucose tolerance, hyperinsulinemic yet glucose-tolerant mice, and prediabe

300 ry and biotelemetry in male Wistar and obese hyperinsulinemic Zucker diabetic fatty (ZDF) rats 45 min